CD8A and neoplasm: ARNAX, a TLR3 agonist, promoted full priming and proliferation of CTLs and enhanced CD8+ T cell infifiltration into the tumor site through TLR3-TIR domain-containing adaptor molecule-1 (TICAM-1)-IRF3-IFN-β axis in DCs.